Introduction
Coronary heart diseases, including myocardial infarction (MI) and ischemic heart disease, are the leading cause of mortality and morbidity worldwide accounting for over 370,000 deaths per year in the United States [1] . It is characterized by severe impairment of coronary blood supply, which produces myocardial ischemic injury accompanied by a wide range of clinical symptoms. Indeed, timely restoration of coronary perfusion or reperfusion is the only known effective therapeutic intervention for protecting the heart against ischemic injury. Although reperfusion salvages viable myocardium, it causes additional (up to 50%) damage known as "reperfusion injury" to the myocardium, increasing arrhythmia, myocardial stunning and infarction size, and thus, diminishing myocardial contraction [2] . Despite continuous intensive studies, including a variety of pharmacological and non-pharmacological (conditional) approaches, there is no effective therapy for preventing cardiac ischemia-reperfusion (IR) injury. Therefore, in addition to restoring coronary perfusion, current therapeutic strategies focus on limiting reperfusion injury [3, 4] .
IR injury is a multifaceted process that affects many aspects of cardiac metabolism including energy metabolism, contractility, ion homeostasis, redox state, and many others. Mitochondria are the central players in cardiac IR injury where the loss of mitochondrial function leads to cell death through apoptosis and necrosis [3, [5] [6] [7] . Importantly, during ischemia, the loss of oxygen compromises mitochondrial ATP production and induces a rise in intracellular Ca 2+ . Reperfusion after severe ischemia further increases intracellular and mitochondrial Ca 2+ accompanied by enhanced generation of reactive oxygen species (ROS). All these factors, along with increased concentration of inorganic phosphate (P i ) and normalization of intracellular pH (pH i ) result in changes in inner mitochondrial membrane (IMM) permeability concurrently with the opening of the non-specific, high-conductance mitochondrial permeability transition pore (PTP) (reviewed in [8, 9] ). Notably, the PTP remains closed during ischemia due to low pH i (<7.0) but it opens during the first minutes of reperfusion with normalization of pH i [10, 11] . In favor of this conclusion, temporary acidosis at reperfusion [12] , and pharmacological inhibition of Na + -H + exchanger 1 (NHE-1), a plasma membrane antiporter [13] [14] [15] , inhibited PTP opening and improved cardiac recovery and mitochondrial function after myocardial infarction (IR). However, the PTP presumably opens during anoxia (hypoxia) due to coronary perfusion that keeps pH i at a relatively normal (>7.0) level. The molecular identity and precise function of the PTP complex is not clear; however, cyclophilin D (CypD) has been widely accepted as a major regulator of the PTP opening [16, 17] . The opening of the PTP during reperfusion further compromises cellular energetics and ultimately results in mitochondria-mediated cell death.
Due to its central role in cell death, inhibition of the PTP opening is the most promising therapeutic strategy for protection and restoration of mitochondrial function during cardiac IR. Since CypD is the only known PTP player whose activation stimulates pore opening, pharmacological targeting of CypD can serve as an adequate approach to protecting the heart against IR injury. Indeed, numerous experimental and clinical studies since the 1990s revealed beneficial effects of CypD inhibitors in animal models of cardiac IR (reviewed in [16, 18] ) and in small groups of patients with MI undergoing percutaneous coronary intervention (PCI) (reviewed in [19] ). However, a recent large multicentre clinical trial that investigated the efficacy of the PTP inhibitor cyclosporine A (CsA) revealed no protective effects of the drug on clinical outcomes in MI patients [20] . Lack of pharmacological efficacy urges for comprehensive reviewing and discussion of the physiological role of CypD as well as PTP opening to clarify whether CypD is a feasible target for cardioprotection. Growing data indicate that CypD, in addition to its role in the mitochondrial permeability transition, may play a pivotal role in regulating overall cell metabolism. Studies including genetic deletion/ silencing or pharmacological inhibition of CypD unveiled its contribution to the sarcoplasmic reticulum (SR)-mitochondria interaction in regulating cytosolic Ca 2+ signaling [21, 22] , and mitochondria-to-nuclei gene expression signaling to direct cell proliferation [23] . Moreover, CypD regulates mitochondrial genome [24] , tricarboxylic acid (TCA) cycle [25, 26] , respiratory function [24, 26] , and oxidative phosphorylation [27, 28] . In addition, CypD is involved in cell metabolism, regulates glucose homeostasis and insulin resistance [26, 29, 30] , and participates in the maintenance of immune and inflammatory responses [31, 32] .
This review summarizes and discusses previous studies on the physiological role of CypD and PTP opening in cellular metabolism and mitochondrial bioenergetics. We believe that complete elucidation of the molecular identity and identification of the mechanisms of the PTP regulation can provide new therapeutic targets aiming to attenuate mitochondria-mediated cell death. The review discusses recent achievements in revealing the molecular identity of the PTP complex as well as recapitulates potential obstacles in PTP targeting.
Molecular identity of the PTP complex: the update
Although pioneering studies in the 1970s by Haworth and Hunter discovered the existence of the PTP [33] , the molecular identity of the pore still remains unclear. By 2004, biochemical and electrophysiological studies obtained by different groups have proposed that adenine nucleotide translocase (ANT) [34] [35] [36] [37] and voltage-dependent anion channel (VDAC) or porin [37, 38] can be the core components of the PTP complex. However, several solid genetic studies in 2004-2007 using ANT and VDAC knockout (KO) animal/cell models have demonstrated pore opening in the absence of the aforementioned proteins [39] [40] [41] [42] , thus suggesting that they are not involved in the PTP assembly. At the same time, a major regulatory role of CypD in PTP formation has been broadly recognized. The roles of ANT and VDAC in PTP induction were reviewed in detail elsewhere [9, 16, 17, 43] and, therefore, we would like to focus on the proteins that were recently proposed as potential PTP core components.
In 2008, Halestrap's group proposed the mitochondrial phosphate carrier (P i C) as a potential PTP core component [44] basing on the fact that a calcium-triggered conformational change of the P i C, facilitated by CypD, induced pore opening. P i C is localized in the IMM and transports P i into the matrix of mitochondria. The studies unveiled the interaction of P i C with CypD and ANT to stimulate PTP opening. Notably, the binding of P i C to CypD was CsA-sensitive while the interaction between P i C and ANT was insensitive to CsA treatment suggesting a regulatory role of the ANT in pore opening [44] . Later, studies of the same group have demonstrated that downregulation of P i C expression by 65-80% with siRNA in HeLa cells had no effect on mitochondrial Ca 2+ accumulation and PTP opening [45] , thus undermining the role of P i C as a core PTP component. However, it was difficult to delineate an important role for the P i C due to incomplete silencing of its expression.
Most recent genetic studies using mice models with cardiac-specific overexpression or downregulation of P i C shed light on whether P i C is involved in the PTP complex [46, 47] . These observations confirmed previous studies that the P i C directly binds to CypD; however, overexpression or knockdown of P i C exhibited a normal PTP response [46] , thus suggesting that the P i C does not appear to be a critical PTP component. Notably, mice with inducible and cardiacspecific deletion of the Slc25a3 gene (P i C protein) developed significant cardiomyopathy [47] , and cardiac mitochondria isolated from these mice demonstrated a greater Ca 2+ retention capacity (CRC), thus assigning a regulatory role to P i C in pore opening.
Spastic paraplegia 7 (SPG7) has been recently suggested as an essential and conserved component of the PTP [48] , although many questions regarding the structural role of SPG7 remain unrevealed [49] . SPG7 is an AAA-protease that co-assembles with a homologous protein, AFG3L, and other unidentified proteins creating complexes with a molecular weight of ~900 kDa in the IMM. It has been shown that the PTP is a heterooligomeric complex containing VDAC, SPG7, and CypD [48] . However, like CypD, ablation of SPG7 did not prevent PTP opening at high concentrations of Ca 2+ suggesting a regulatory rather than the structural role of SPG7 in PTP induction. Furthermore, it is still not clear whether the complex composed of VDAC, SPG7, and CypD can function as a channel.
One of the potential candidates that are intensively assessed as a PTP core component is F O F 1 -ATP synthase (complex V). ATP synthase consists of two protein entities (domains), F 1 and F O , that comprise 17 different types of subunits accounting for a total of more than 30 subunits in mammalian mitochondria. The catalytic domain F 1 situated in the mitochondrial matrix consists of five different subunits (α, β, γ, δ and ε), whereas the membrane domain F O includes the regular subunits c, a, b, d, F6, oligomycin sensitivity-conferring protein (OSCP) and the accessory subunits e, f, g and A6L. The F 1 subunits γ, δ and ε constitute the central stalk while the F O subunits b, d, F6 and OSCP form the peripheral stalk of ATP synthase. The subunits a and A6L of the F O domain are the only ATP synthase subunits encoded by the mitochondrial DNA (mtDNA) [50] . These subunits are responsible for stabilization of the ATP synthase structure, particularly, for monomer-monomer interaction during dimerization of two ATP synthase monomers via the F O domain.
The capacity of ATP synthase to form a supercomplex structure (ATP synthasome) through its dimerization, and interaction with P i C and ANT [51, 52] , made it an attractive candidate for the PTP complex. Initial studies demonstrate that P i increased CypD binding to the lateral stalk of ATP synthase and decreased its enzyme activity in bovine heart mitochondria. Dissociation of the CypD-ATP synthase complex by CsA reversed the enzyme activity of ATP synthase [27] . This study left open the question whether the interactions of CypD with the ATP synthase are related to the PTP induction.
In 2013, genetic studies revealed a crucial role of the c-subunit of ATP synthase in Ca 2+ -induced PTP opening in Hela cells [53] . This observation was further supported by studies where the purified reconstituted c-subunit ring of the F O domain formed a voltage-sensitive channel, and the persistent opening of the channel by Ca 2+ led to a rapid and uncontrolled depolarization of the IMM [54] . High matrix Ca 2+ enlarged the c-subunit ring which was disconnected from CypD-binding sites in the F 1 domain leading to PTP opening. Interestingly, the purified c-subunit added to mitochondria induced CsA-sensitive PTP induction, which was affected by the phosphorylation/dephosphorylation status of the c-subunit [55] . Nevertheless, it remains unclear whether the c-subunit plays a structural or regulatory role in the PTP activity.
Bernardi's group proposed an interesting model according to which purified dimers of the ATP synthase reconstituted into lipid bilayers exhibited the PTP-like activity [56] . However, subsequent studies from the same group showed that Rho 0 cells depleted of mtDNA still displayed the PTP activity [57] . As aforementioned, the subunits a and A6L encoded by mtDNA are important for dimerization of ATP synthase and the PTP activity in Rho 0 cells excludes the role of ATP synthase dimers in forming the PTP. Thus, although several studies confirm a regulatory role of the ATP synthase in PTP activity, a structural role of the synthase remains unknown. Taken together, current studies suggest a possible regulatory or essential role of ATP synthase through the following two mechanisms: (1) dimerization of ATP synthase molecules apparently through the contact sites between monomers to form the PTP, and (2) conversion of the c-subunit ring in the F O domain to the non-selective PTP. However, further studies are certainly needed to confirm if the ATP synthase is a core structural component of the PTP.
Overall, despite intensive and numerous studies, the molecular identity of the PTP complex has not yet been established. The majority of proteins initially known as classic core components of the PTP complex actually participate in the regulation of PTP induction (Fig. 1 ).
Physiological role of CypD
Mammalian cells contain 17 cyclophilins and all of them are encoded by the nuclear genome, particularly, by the peptidyl-prolyl cis-trans isomerase (PPIase) gene (Ppif). The main isoforms of cyclophilins are CypA, CypB, CypD, CypE, Cyp40 and CypNK that are localized in different subcellular compartments including the cytoplasm, nucleus, sarcoplasmic reticulum and mitochondria [58, 59] . CypD is the only mitochondrial cyclophilin encoded by Ppif that after synthesis in the cytoplasm is translocated to the mitochondria. Upon translocation to the mitochondria, a mitochondrial localization sequence is cleaved leading to the mature form of CypD with a molecular weight of ~21 kDa [60] . PTP-dependent and PTP-independent physiological and pathological functions of CypD are summarized in Fig. 2 .
Physiological functions of cyclophilins, particularly CypD, have not yet been fully understood. Cyclophilins are the primary binding targets of immunosuppressive agents such as CsA and its derivatives. CypD, like other cyclophilins, catalyzes the cis/trans isomerization of peptidyl-prolyl bonds in proteins [61] . Cyclophilins possess the ability to catalyse the protein folding [62] , and CypD contains an N-terminal targeting sequence that participated in translocation of proteins from the cytoplasm to the mitochondria. Previous studies have reported the existence of cyclophilins in the intermembrane space to catalyse folding of newly imported proteins; however, it remains unclear, whether CypD is involved in protein folding in the intermembrane space [60, 63] .
CypD as a regulator of mitochondrial Ca

2+
Growing data suggest that CypD through a low-conductance PTP opening participates in the regulation of mitochondrial Ca 2+ homeostasis. Pioneering studies demonstrated that CsA inhibits Ca 2+ release from mitochondria in rat cardiomyocytes [64] .
PTP flickering in a low-conductance mode, which is permeable to solutes, mostly ions, with a molecular weight less than 300 Da, induces negligible matrix swelling [65] .
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CypD ANT P i C [64, 66] . Apparently, short openings of PTP induces partial dissipation of Ψ m and the fast release of accumulated Ca 2+ from the matrix thus serving as an emergency mechanism [67] . In addition, mitochondria are excitable organelles that generate and convey electrical and Ca 2+ signals. In this aspect, CypD through the opening of the low-conductance PTP can initiate mitochondrial depolarization spikes and generate Ca 2+ waves through Ca
2+
-induced release of Ca 2+ from one mitochondrion to another [68] . Conversely, mice lacking CypD exhibited elevated levels of matrix Ca 2+ presumably due to reduced physiological opening of the PTP [25] .
Several studies questioned the role of CypD to increase mitochondrial Ca 2+ efflux through the PTP. Pharmacological or genetic inhibition of CypD had no effect on mitochondrial Ca 2+ release in HeLa cells [69] . Studies using CsA in isolated guinea pig cardiac mitochondria reported a negligible role of PTP in Ca 2+ efflux compared to that mediated by mitochondrial Na + /Ca 2+ exchange [70] . The extent of mitochondrial Ca 2+ overload and the amount of CsA should, apparently, be taken into consideration to assess the PTP-induced Ca 2+ release. CsA has beneficial effects at a narrow range of concentration (0.2-1.0 µM), whereas at high concentrations (>2 µM), it exerts detrimental effects in isolated cardiomyocytes [71] and cardiac mitochondria [70] , and aggravates IR injury [72] . It has been suggested that the toxic effects of CsA depend on the extracellular [Ca 2+ ] [71] and that increased mitochondrial Ca 2+ loading could potentially contribute to detrimental effects of CsA at high concentrations [70] .
In addition to Ca 2+ efflux, several studies demonstrated a possible role of CypD in Ca 2+ uptake into the mitochondria. CsA at high concentrations (1-10 μM) inhibited mitochondrial Ca 2+ uptake induced by the MCU activator SB202190 in HeLa cells. Interestingly, this effect was not mimicked by another PTP (bongkrekic acid) or calcineurin inhibitors (FK-506 or cypermethrin) suggesting that CsA inhibits Ca 2+ influx through the MCU by a mechanism, which is independent of PTP or calcineurin [73] . Several studies demonstrated a crosstalk between endoplasmic reticulum and the mitochondria that modulates Ca 2+ uptake and release during cardiac IR injury, which can serve as a target for pharmacotherapy to reduce PTP induction and cell death (Reviewed in [74] ). Genetic or pharmacological inhibition of CypD in H9c2 cardiomyoblasts and adult cardiomyocytes reduced the Ca 2+ transfer from the SR to the transfer from the SR to the mitochondria. However, it is not clear whether other cyclophilins (e.g. CypA) in the cytoplasm and the SR are involved in the inhibitory effects of CsA on the SR-mitochondria interaction. Indeed, CypA was shown to bind to the Ca 2+ storage protein of the endoplasmic reticulum calreticulin [75] suggesting a possible role of cyclophilins in regulating cytosolic Ca 2+ signaling through modulation of the mitochondrial and ER Ca 2+ uptake. It should be pointed out that several other studies unveiled the capacity of CsA to enhance Ca 2+ uptake into the mitochondria. CsA increased mitochondrial Ca 2+ accumulation and reduced maximum respiration rate (state 3) of mitochondria [76] . In addition, CsA reduced Ca 2+ uptake in the endoplasmic reticulum and mitochondria and thus, inhibited IP 3 -dependent Ca 2+ signals in intact hepatocytes [22] . These studies could designate a possible role of CypD in regulating mitochondrial Ca 2+ uptake; however, contradictory data observed in similar studies might be due to the toxic effects of CsA at high concentrations.
Thus, CypD, apart from regulating cell death, presumably plays an important physiological role in the cell through regulation of energy metabolism and Ca 2+ homeostasis. Ppif −/− mice developed greater cardiac hypertrophy and myocardial dysfunction in response to pressure overload or sustained exercise stimulation [25] . In addition to a cardiac phenotype, cardiac mitochondria isolated from Ppif −/− mice exhibited elevated levels of matrix Ca 2+ and high activity of Ca 2+ -dependent dehydrogenases due to altered Ca 2+ efflux. Importantly, cardiomyocyte-specific transgene expression of CypD in Ppif −/− mice rescued the functional alterations. This study suggests an important physiological function for CypD and PTP to maintain Ca 2+ homeostasis in mitochondria and thus, regulate metabolism and timely response to myocardial workload.
CypD and cellular energy metabolism
Several studies provide evidence that CypD is involved in the regulation of energy metabolism in cells. Currently, PTP-independent role of CypD in glucose and fatty acid metabolism are intensively debated. The ability of CypD to regulate insulin production and glucose homeostasis was confirmed recently in CypD KO mice in vivo wherein the glycolytic shift due to CypD deletion was associated with increased number of insulin-producing islet β cells, mild hyperinsulinemia, improved glucose tolerance, and resistance to high-fat diet-induced liver damage and weight gain compared to WT animals [26] .
Genetic or pharmacological inhibition of CypD prevented insulin resistance due to increased glucose uptake through insulin-stimulated translocation of GLUT4 to the plasma membrane in skeletal muscle. Mitochondria isolated from the skeletal muscle exhibited low PTP opening associated with improved CRC but without changes in insulin signaling [30] . However, in mouse and human primary hepatocytes, inhibition of CypD had opposite effects and diminished insulin sensitivity. Overexpression of CypD enhanced insulin action associated with changes in ER-mitochondria interaction [29] . Based on these data, CypD apparently participates in insulin resistance and glucose uptake, which can be regulated differently depending on the tissue/cell type. It is not clear whether the observed effects of CypD on insulin resistance and glucose uptake are secondary to PTP inhibition or if they result from a PTP-independent action of CypD.
Recent studies using both loss-and gain-of-function approaches provided strong evidence that CypD is an important positive regulator of mitoflash activity in the heart through modulation of mitoflash frequency [77] . The mitoflashes may include mitochondrial concurrent and sudden ROS burst, ΔΨ m dissipation, NADH depletion, transient permeability transition, and matrix alkalization [77, 78] . Since mitoflashes are involved in the regulation of cell metabolism and signaling [79] , modulation of mitoflash activity by CypD [77] suggests that it plays a significant role in maintaining cellular metabolism including, among others, heart mitochondrial bioenergetics under physiological and pathological conditions in the heart.
The role of CypD in the regulation of mitochondrial bioenergetics
CypD can regulate ATP synthesis through changes in mitochondrial Ca 2+ by a low-conductance PTP induction. Calcium stimulates mitochondrial dehydrogenases thereby increasing NADH and FADH 2 resulting in a rise in ATP synthesis [80] . Small or transient changes in the matrix [Ca 2+ ] can be regulated, in addition to other mechanisms, by transient PTP opening. Hearts of Ppif −/− mice showed an increase in the succinate to glutamate ratio suggesting stimulation of the TCA cycle flux in the absence of CypD. In favor of this, the activities of the Ca 2+ -regulated mitochondrial enzymes pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase (αKGD) were significantly enhanced in Ppif −/− hearts with no differences in protein expression levels of these and other two Ca 2+ -regulated mitochondrial dehydrogenases [25] . These data suggest that the increase in enzymatic activity might be due to high mitochondrial [Ca 2+ ]. CypD depletion had no effect on respiratory function in isolated cardiac mitochondria [81] ; however, CypD-null cardiomyocytes revealed reduced mitochondrial maximal respiration rate and reserved capacity [77] . Likewise, significant defects in mitochondrial TCA and fatty acid oxidation (FAO) associated with reduced oxygen consumption were observed in mouse embryonic fibroblasts (MEFs) from CypD KO mice [26] . CypD silencing can reduce ΔΨ m and oxygen consumption in HEK293T cells and downregulated mtDNA-encoded transcripts for subunits of ETC complexes [24] .
There was no difference between WT or CypD KO mice in the activity of individual ETC complexes in liver [26] and cardiac [82] mitochondria. CypD deficiency had no effect on supercomplex I + III + IV (respirasome) levels but reduced the yield of mitochondria and citrate synthase activity in the mouse heart [82] . On the other hand, CypD −/− hearts showed decreased FAO rates and increased oxidation of glucose. CypD ablation reduced acylcarnitines levels in the heart apparently due to lower expression of carnitine-palmitoyltransferase 1 (CPT1), an enzyme that catalyzes the reaction which converts acyl-CoA to acylcarnitine on the outer mitochondrial membrane, in CypD −/− hearts [81] . In MEFs, unlike the heart, impaired FAO induced by CypD deletion was associated with increased accumulation of acylcarnitines [26] . In this study, liver extracts from CypD KO mice exhibited significantly reduced activity of the mitochondrial trifunctional protein (TFP) compared to its WT counterparts. The TFP is a multienzyme complex of the mitochondrial β-oxidation, a dominant energy-producing metabolic pathway in the heart [26] .
Recent studies on the role of CypD in regulating ATP synthase open new avenues in understanding the role of CypD in energy metabolism. CypD has been shown to interact with the ATP synthase through binding to the lateral stalk, and the ATP synthase-CypD interaction could modulate the complex's enzymatic activity in intact bovine heart mitochondria [27]. Phosphate increased CypD binding and decreased the activity of ATP synthase, whereas CsA, in contrast, decreased CypD binding and upregulated the activity of the enzyme. Interestingly, CsA has no effect on mitochondria isolated from Ppif −/− mice, which exhibited a higher specific activity of the ATP synthase than WT mitochondria, suggesting a regulatory role of CypD in ATP synthesis [27] . Inhibition of the ATP synthase activity by CypD binding may reduce energy dissipation under oxidative stress when the enzyme acts in a reverse mode hydrolyzing ATP. Thus, increased [Pi] stimulates CypD binding to the ATP synthase. Interestingly, genetic ablation or pharmacological inhibition of CypD increased the ATP synthase activity associated with slightly increased respiration rates but did not affect ANT-mediated ADP-ATP exchange rates in intact mitochondria [28] . CypD binding could affect oligomerization of the ATP synthase favoring PTP formation although it may modulate the enzymatic activity independently of the PTP induction. Recent studies unveiled downregulation of ATP6, a mtDNA-encoded subunit of F O F 1 -ATPase in CypD-silenced cells that was consistent with reduced oxidative phosphorylation [24] .
Taken together, CypD presumably participates in regulating both glucose and fatty acid metabolism as well as mitochondrial bioenergetics including TCA cycle, ETC and oxidative phosphorylation in the cell in a tissue/organspecific manner. However, the physiological role of PTP in mediating the effects of CypD on energy metabolism remains elusive. Since mitochondria are highly sensitive to small changes in matrix volume [83] , mitochondrial metabolism can be regulated by a low conductance PTP when volume-mediated increases over the physiological range can stimulate mitochondrial bioenergetics.
Modulation of CypD activity
The mechanisms of activation of CypD and its interaction with the PTP complex to regulate pore opening have not been discovered. The lack of knowledge on the molecular identity of the pore affects understanding the regulatory role of CypD in PTP activation. Genetic studies questioned the role of VDAC, ANT, P i C, and ATP synthase as the core components of the PTP complex although they play a regulatory role in pore formation. Also, the interaction of CypD with VDAC, ANT, P i C, and ATP synthase may not be associated with the PTP induction and can regulate PTP-unrelated functions of these proteins. Hypothetically, regulation of the PTP can occur through several mechanisms of interaction between CypD and a target protein(s) in the IMM. Apparently, activation of CypD and/or target protein(s) is necessary for stimulation of PTP induction. CypD can bind to a target protein in the IMM and induce PTP opening through the interaction of CypD alone (direct binding) or in complex with a matrix protein (indirect binding). Changes in PPIase activity of CypD resulted from posttranslational modifications or other mechanisms can affect its binding to a PTP core protein as well as PTP regulatory proteins including ANT, P i C and/or ATP synthase to modulate PTP induction.
Post-translational modifications of CypD
The activity of CypD to stimulate or inhibit PTP induction can be regulated by post-translational modifications (PTMs). Post-translational modifications of CypD by phosphorylation, nitrosylation, oxidation or acetylation have been shown to modulate pore opening (Fig. 3) .
Phosphorylation
There are a limited number of studies demonstrating phosphorylation of CypD. Cardioprotective effects of glycogen synthase kinase 3β (GSK-3β) were associated with its translocation from cytosol to mitochondria via the cGMP/ PKG pathway where it interacted with CypD, but not VDAC and ANT [84] . However, it is not clear if the beneficial effects were due to GSK-3β-induced phosphorylation of CypD in this study. Active recombinant GSK was shown to directly phosphorylate CypD at Ser/Thr and phosphoCypD promoted depolarization of mitochondria and PTP opening in tumor cells [85] . ERK1/2 inhibition stimulated GSK-3-dependent phosphorylation of CypD, whereas GSK-3 inhibition protected mitochondria from PTP opening. Furthermore, ERK1/2 inhibition increased mitochondrial depolarization in cells overexpressing CypD, and was ineffective in CypD KO cells suggesting a critical role of the ERK1/2-GSK-3-CypD axis in mitochondria-mediated cell death in cancer cells [85] . Conversely, pharmacological inhibition of GSK-3β prevented CypD phosphorylation and inhibited PTP opening in murine tubular epithelial cells [86] . Given the complexity of translocation of protein kinases to mitochondria and their role in phosphorylation/dephosphorylation of matrix proteins, further studies are required to clarify the mechanisms of CypD phosphorylation.
S-Nitrosylation
Protein S-nitrosylation (SNO) has emerged as an important post-translational modification that protects the heart against IR injury [87, 88] . Nitric oxide (NO) can exert opposite effects on the PTP; low NO levels inhibit while high NO stimulate pore opening [89, 90] . Nitrosylation through covalent attachment of NO to a protein's cysteine residue has been shown to exert cardioprotective effects [91] . However, NO can interact with ROS and produce a highly toxic and more powerful oxidant peroxynitrite (ONOO−) during severe oxidative stress. In vitro, NO and ONOO− initiated permeabilization of mitochondrial membranes, and this effect was inhibited by CsA, indicating the involvement of the PTP complex in the permeabilization. Nitric oxide and ONOO− also attacked ANT, a PTP regulator that binds CypD, to permeabilize ANT-containing proteoliposomes [92] . Neuronal mitochondria contained increased nitration of CypD and ANT on tyrosine consistent with PTP and cell death after cortical injury [93] .
Post-translational modification of CypD induced by SNO can regulate PTP activation. Heart homogenates treated with an NO donor, GSNO, exhibited increased SNO of CypD on Cys203 [87] . To further investigate the role of Cys203 in PTP activation, Cys203 of CypD was mutated to a serine residue (C203S) [94] . Mouse embryonic fibroblasts reconstituted with C203S-CypD were resistant to H 2 O 2 -induced PTP opening in the presence or absence of GSNO. Likewise, liver mitochondria isolated from CypD −/− mice or mice expressing C203S-CypD were resistant to Ca 2+ -induced swelling compared to WT mice. Pretreatment with GSNO attenuated H 2 O 2 -induced PTP opening in MEFs isolated from WT but not CypD KO mice. These studies suggest a critical role of the Cys203 residue in PTP activation although the contribution of Cys203 nitrosylation to pore induction remains unclear [94] . CypD SNO at Cys203 could prevent protein-protein interactions between CypD and PTP component(s) and thereby, inhibit pore opening [88] . Further studies are required for understanding the precise mechanisms through which CypD SNO regulates the PTP activity.
Oxidation
Oxidation of CypD has implicated in the modulation of the mitochondrial redox state. Hydrogen peroxide-induced oxidation of CypD affected its conformation and enzymatic activity, and oxidized CypD could stimulate PTP induction and cell death [95] . These studies identified Cys157 and Cys203 by site-directed mutagenesis as the only residues that influence the redox conformation of CypD due to the formation of an intramolecular disulfide bridge. It was suggested that CypD might act as a redox sensor and regulate redox environment in mitochondria. Conversely, liver mitochondria expressing the CypD mutant Cys203Ser were resistant to Ca 2+ -induced PTP opening [94] . Oxidative stress in fibroblasts from patients with X-linked adrenoleukodystrophy induced oxidative modifications in CypD and increased its protein expression levels [96] .
Recent studies found that the mitochondrial thioredoxin system, a major redox regulator, stimulated the PPIase activity of CypD in isolated rat heart mitochondria, and the effect was prevented by CsA and the thioredoxin reductase inhibitor auranofin. Hydrogen peroxide induced a concomitant oxidation of thioredoxin and CypD suggesting a link between these two components [97] . These studies show that the thioredoxin system of the mitochondria controls the redox state of CypD through a specific redox signaling whereby the thiol redox changes can modulate CypD. The redox conditions of CypD can regulate the PTP by acting the activity of ANT, P i C, ATP synthase, and other PTPrelated proteins containing redox-sensitive thiols.
Acetylation
Post-translational modification of proteins through acetylation/deacetylation plays an important regulatory role in mitochondrial metabolism. Deacetylation of mitochondrial proteins is catalyzed by a major mitochondrial isoform of sirtuins, sirtuin-3 (SIRT3), a NAD + -dependent deacetylase. Several studies suggested a possible role of CypD acetylation in PTP activation. Deacetylation of CypD by SIRT3 diminished its PPIase activity and induced its dissociation from ANT in cancer cells [98] . Conversely, inhibition of the SIRT3 activity by ethanol enhanced the acetylation and activity of CypD associated with increased interaction between CypD and ANT-1 [99] . Wild-type but not a catalytically inactive SIRT3 (SIRT3-H248Y mutant) deacetylated CypD on Lys166, adjacent to the binding site of CsA in 293T cells emphasizing the role of SIRT3 to deacetylate CypD-K166 [100] .
Only a few studies investigated the role of CypD acetylation in cardiac diseases. Post-MI heart failure increased acetylation of CypD and reduced SIRT3 expression in rats [101] . Decreased CypD acetylation and increased SIRT3 expression was associated with improved cardiac function and mitochondrial respiration. Likewise, SIRT3 overexpression prevented CypD acetylation, inhibited PTP opening, and reduced cell death induced by IR in H9C2 cells [102] . Cells expressing non-acetylable CypD mutant (CypD-KR) demonstrated less cell death after IR compared to cells expressing intact CypD WT. Ischemic postconditioning could not reduce infarct size and CypD acetylation in SIRT3 KO mice [102] , suggesting that deacetylation of CypD plays a pivotal role in cardioprotection against IR. SIRT3 KO mice were hypersensitive to heart stress induced by transverse aortic constriction (TAC) and developed more cardiac hypertrophy and fibrosis compared to WT animals [100] . These data suggest that SIRT3-dependent CypD acetylation is involved in the pathogenesis of cardiac hypertrophy. Lack of data on the cause-effect relationship makes it difficult to underline an exact contribution of CypD acetylation to the development of hypertrophy. Interestingly, CypD KO mice exhibited substantially greater cardiac hypertrophy and fibrosis associated with myocardial dysfunction in response to pressure overload than WT mice [25] . Conversely, cardiomyocyte-specific transgene expression of CypD rescued the pressure overload-induced hypertrophy and cardiac dysfunction in Ppif −/− mice. Interestingly, CypD per se can participate in modulating protein acetylation in mitochondria by a yet unknown mechanism(s). Analysis of acetylated proteins in cardiac mitochondria isolated from WT and Ppif −/− mice found increased acetylation of proteins involved in FAO and branched-chain amino acid metabolism in Ppif −/− samples [103] . Hyperacetylation of FAO proteins, e.g. l-3-hydroxyacyl-CoA dehydrogenase, in Ppif −/− hearts was associated with reduced enzymatic activity of these proteins compared with the WT mitochondria. These results suggest that ablation of CypD causes substantial changes in the mitochondrial acetylome, which may contribute to altered mitochondrial metabolism in Ppif −/− hearts. Thus, the role of CypD acetylation in regulating pathological signaling network through the PTP is controversial and desires further studies. Notably, the contribution of CypD to modulate cardiac metabolism and function was demonstrated only in the presence of genetic overexpression or downregulation of SIRT3 and, thus, whether endogenous SIRT3 deacetylates CypD in the mitochondria remains to be elucidated. It is not clear if SIRT3 has or not an additional direct effect on cardiac hypertrophy and IR independent of PTP opening.
Overall, the role of PTMs of CypD in the regulation of PTP opening remains elusive. To date, only four types of PTMs of the CypD molecule have been studied. Phosphorylation, oxidation and acetylation of CypD were associated with PTP activation whereas CypD nitrosylation attenuated the PTP (Fig. 3) . Although several studies demonstrated an association between PTMs of CypD and PTP induction, a cause-effect relationship between these events have not been fully investigated. Furthermore, acetylation of CypD was only investigated in cardiomyocytes and cardiac mitochondria, which is an obstacle to understand the role of PTMs of CypD in IR injury and cardioprotection.
Interaction of CypD with other proteins
In addition to post-translational modifications, interaction with proteins in the matrix and IMM can modulate the CypD activity and PTP opening (Fig. 4) -triggered conformational change of the ANT was facilitated by CypD which had a high PPIase activity [35] . CsA-sensitive binding of CypD to the ANT stimulated PTP opening in isolated heart and liver mitochondria [104, 105] . Later studies revealed that in vitro oxidative stress antagonized adenine nucleotide binding to the ANT, enhanced CypD-ANT interaction, and stimulated Ca 2+ -induced PTP opening [106] . Chemical modifications on Cys56, Cys159 and Cys256 of the ANT by oxidative stress or thiol reagents caused a conformational change of the protein [107] . Additionally, two distinct thiol groups in the ANT have been shown to modulate the PTP activity [108] . The thiol groups were suggested to work as a regulator of the binding affinity of ANT for CypD and ADP [109] . Moreover, cross-linking of two matrix facing cysteine residues (Cys56 and Cys159) of ANT, induced by oxidative stress or thiol reagents was shown to enhance CypD-ANT interaction and PTP activity [110] . Thus, thiol oxidation of ANT and/or Ca 2+ can facilitate the interaction of CypD with ANT and stimulate pore opening. Although genetic studies questioned the role of ANT as a core PTP component, growing data have implicated the ANT-CypD interaction in the regulation of PTP activity.
Subsequent studies revealed interaction of CypD with P i C that was stimulated by oxidative stress and thiol reagents thereby increasing PTP opening [44] . Inhibition of ANT with carboxyatractyloside increased the CypD-P i C interaction in liver mitochondria suggesting a crosstalk between the PTP regulatory proteins. Interestingly, CypD binding to ANT and P i C is blocked by CsA but not sanglifehrin A (SfA), a close analog of CsA; the latter even increases CypD interaction with these proteins [44] . Precise mechanisms of opposite effects of CsA and SfA on the binding of CypD with ANT and P i C are not clear. Sanglifehrin A, but not CsA, inhibits the PPIase activity of CypD with no effect on its interaction with ANT and P i C. Unlike CsA, SfA induces dimerization of CypA [111] and CypD [112] . In addition, dependence between CsA concentration and PTP inhibition is linear, whereas between SfA and PTP inhibition is sigmoidal and, therefore, SfA has a negligible inhibitory effect on PTP opening at low concentrations [112] . The interaction between CypD and Numerous proteins in the matrix activated or inhibited PTP induction through interaction with CypD. In brain IR, the tumor suppressor protein p53 translocated to the mitochondrial matrix, where it interacted with CypD and caused PTP opening [113] . Conversely, ablation of p53 or pharmacological inhibition of CypD with CsA induced dissociation of the p53-CypD complex and prevented pore opening that was associated with effective protection from stroke injury [113] . In favor of this, the role of mitochondrial CypD-p53 signaling in PTP-induced cell death was subsequently reported in pancreatic cancer cells [114] , neuronal cells [115] , and osteoblasts [116] . These findings suggest translocation of the p53-CypD complex to the IMM where it triggers the pore opening through interaction with PTP core protein(s). Indeed, when localized in the mitochondrial matrix, p53 specifically interacted with the F O F 1 -ATP synthase subunit OSCP in human colorectal carcinoma HCT116 cells [117] . However, many questions regarding the contribution of the p53-CypD interaction to pore opening remain unanswered. Indeed, the p53 inhibitor pifithrin-α prevented loss of ΔΨ m and inhibited PTP opening in angiotensin II-treated H9c2 cardiomyoblasts but there was no interaction of p53 with CypD, ANT or VDAC [118] . Calcium-dependent PTP opening was not regulated by p53 [113] raising a concern on how the p53-CypD complex induces Ca 2+ -independent opening of the PTP [119] . It should be noted that the p53-CypD complex may be involved in PTP-induced cell death through distinct mechanisms in cancer and normal (non-cancer) cells.
Complement 1q-binding protein (C1qbp), a C1q-binding receptor found in subcellular compartments including mitochondria, was involved in PTP induction [120] . Recent gain-and loss-of-function studies revealed that C1qbp KO sensitized MEFs to H 2 O 2 -induced PTP opening and cell death whereas overexpression of the protein had opposite effects and protected the cells from oxidative stress [121] . C1qbp was found to bind to CypD suggesting that it appears to act as a PTP inhibitor through CypD, and protect the cells against oxidative stress.
We have recently demonstrated that oxidative stress induced by H 2 O 2 in H9c2 cardioblasts [122] and in vivo IR in rat hearts [123] stimulates translocation of the peroxisome proliferator-activated receptor alpha (PPARα), a transcription factor and a major regulator of FAO, to the mitochondria and increases its interaction with CypD. The AMPK activators metformin and A-769662 as well as the CypD inhibitor SfA prevented protein-protein interaction between CypD and PPARα and improved cell survival and post-ischemic cardiac recovery [122, 123] . Although these studies suggest a possible role of the PPARα-CypD interaction to stimulate PTP opening, many questions on the cause-and-effect relationship between these two events remain to be elucidated. Moreover, it is not clear how and which PTP core component(s) interacts with the PPARα-CypD complex.
Notably, unlike cardiac IR, CypD has opposite effects in tumor cells, where it reduces PTP-induced apoptosis and necrosis [124] [125] [126] . Although the mechanisms underlying this effect remains unclear, the effects of CypD were explained to be in part associated with hexokinase II binding to the mitochondria [127] . CypD was found upregulated in human tumors including breast, ovarian, or uterus cancer specifically associated with repressed ANT-1-induced apoptosis [125] . These studies suggest that upregulation of CypD in carcinogenesis inhibits opening of the PTP. Interestingly, interaction of the multi-chaperone complex comprising of heat-shock protein 60 (Hsp60), Hsp90, and tumor necrosis factor receptor-associated protein 1 (TRAP1) with CypD was shown in tumor but not in normal mitochondria. Normal (non-tumor) mitochondria contain low levels of these chaperones which have no physical interaction with CypD. Genetic targeting of Hsp60 by siRNA prevented interaction of the chaperon protein with CypD thereby stimulating PTP opening. These data suggest that the cytoprotective chaperone network containing Hsp60, Hsp90 and TRAP1 antagonizes CypD-mediated cell death in tumors [128, 129] .
Interestingly, chaperone proteins and translocation of precursor proteins into mitochondria are both regulated by J-proteins. Human mitochondria consist of two J-proteins with the primary protein import activity, DnaJC19 and DnaJC15 [130] . Overexpression of DnaJC15 resulted in PTP opening and apoptosis, whereas reduced amount of DnaJC15 suppressed PTP in cisplatin-treated normal and cancer cells. Importantly, DnaJC15 interacted with CypD which was associated with its concomitant release from the CypD-TRAP1 complex [131] . Likewise, interaction of mammalian sterile 20-like kinase 1 (MST1) with CypD was involved in gemcitabine-induced pancreatic cancer cell death that was attenuated by MST1 or CypD shRNA silencing, but was aggravated by their overexpression [132] . On the other hand, interaction of CypD with a major anti-apoptotic protein Bcl-2 significantly attenuated cell death and CsA disrupted the CypD-Bcl2 interaction. Overexpression of CypD and its effect through the CypD-Bcl2 complex may be an additional mechanism of suppression of apoptosis in cancer cells [133] . However, it is not clear, how the interaction of CypD with apoptotic proteins modulates the PTP activity in non-tumor cells.
In conclusion, a growing body of studies demonstrate that CypD can interact with several proteins in the matrix and IMM and thus, modulate the PTP activity. However, the precise mechanisms of the cause and effect relationship between protein-protein interactions and PTP opening remain unknown. Apparently, PTP opening is a complex interplay of several CypD-dependent and CypD-independent regulatory mechanisms. Studies on CypD binding to other mitochondrial proteins have been mostly shown in non-cardiac mitochondria and under normal physiological conditions. Therefore, it is difficult to stipulate the contribution of interaction CypD with other proteins in the regulation of PTP to cardiac IR injury and cardioprotection.
CypD as a target for cardioprotection against IR injury Experimental studies
All clinical and experimental studies elucidating the cardioprotective action of PTP inhibition are mostly focused on targeting CypD which is the only broadly accepted PTP regulator. Among other CypD inhibitors, the immunosuppressive drug CsA has been extensively used to verify cardioprotective effects of PTP inhibition against IR injury. It should be noted that CsA was initially used only for immunosuppression during organ grafting, to suppress rejection after internal organ transplantation through inhibition of cyclophilins (immunophilins) and calcineurin [134, 135] . CsA was first used as an immunosuppressive drug in human kidney transplantation in the late 1970s and thus, opened a new era for the treatment of end-stage organ damage in patients-recipients of cadaveric organs [136, 137] . Notably, persistent treatment of patients undergoing organ transplantations with CsA was associated with side effects, including nephrotoxicity, hypertension, and tremor, among others. In initial animal studies, CsA was used at high doses (>20 mg/kg) and had no beneficial effects on renal ischemic injury [138, 139] . In the late 1980s, first studies showed the beneficial effect of CsA (10 mg/kg) on liver ischemia in dogs [140] and rats [141] preventing necrotic damage and increasing mitosis of hepatocytes.
Discovery of CypD with cyclosporin-sensitive PPIase activity in liver and heart mitochondrial-matrix fractions and its interaction with ANT in the presence of Ca 2+ to cause PTP opening [35, 142] motivated further studies on the protective action of CsA against IR injury. First studies in 1991 demonstrated that CsA at low doses (<1 µM) attenuated anoxia-induced injury in isolated cardiomyocytes [143] and protected against IR-induced damage in Langendorff-perfused rat hearts [72] . Since then, many studies using various MI and IR models in mice [144, 145] , rats [72, 146, 147] , rabbits [148] [149] [150] , and pigs [151, 152] provided strong evidence that CsA and its analogs reduce infarct size and improve post-ischemic recovery of the heart. Cardioprotective effects of CsA and its analogs were not associated with inhibition of the calcineurin activity since the specific inhibitor of calcineurin, FK-506, had no beneficial effects on cardiac IR [150, 153] . On the other hand, several new CsA analogs such as SfA [112, 147] , NIM811 [149, 154] and Debio-025 [155] , which do not inhibit the calcineurin activity, protected hearts from IR injury.
Interestingly, a systematic review and meta-analysis of 29 published studies describing the efficacy of CsA using in vivo animal models of acute reperfused MI in 2012 [156] found that CsA had variable effects on infarct size compared with placebo. Notably, not all of the studies exhibited positive results and importantly, large animal studies using a porcine model of reperfused MI [157, 158] reported no beneficial effects thus undermining the potential cardioprotective action of CsA in patients. In addition, a growing body of studies provide strong evidence that spatially distinct subpopulations of cardiac mitochondria known as subsarcolemmal (SSM) and interfibrillar (IFM) mitochondria display functional and structural heterogeneity (Reviewed in [159, 160] ). Animal studies elucidating PTP opening and cardioprotective effects of CsA were carried out mostly on SSM. Isolated cardiac IFM demonstrated a higher CRC and were more resistant to high [Ca 2+ ] compared to SSM [161] . On the other hand, our studies on cultured cardiomyocytes revealed increased level of oxidized flavoproteins and higher Ca 2+ accumulation in SSM [162] . Therefore, evaluation of both mitochondrial subpopulations of the heart is important for understanding the mechanisms of cardioprotective action of PTP inhibition. Furthermore, cardiac mitochondria demonstrate sex and age differences in the sensitivity to Ca 2+ that should be taken into consideration. Female cardiac mitochondria demonstrated lower Ca 2+ uptake rates under physiological conditions [163] and were more resistant to high Ca 2+ with no differences in CypD levels compared to male mitochondria [164] . Cardiac mitochondria isolated from female rats were more efficient and generated less ROS than male rats [165] . These data are in line with other sex-based differences such as lower expression of apoptotic genes in female rat hearts compared to males at all ages [166] . Based on these studies, females may have better preservation of hearts in response to oxidative stress. Interestingly, SfA prevented IR-induced PTP opening in adult but not in neonatal rats [167] suggesting that lower sensitivity to PTP opening may explain the higher tolerance of neonatal hearts to IR injury.
It should be noted that both genetic [40, 168] and pharmacological inhibition [35] of CypD by CsA and its analogs fails to induce complete inhibition of the PTP, especially at higher Ca 2+ when, despite CypD inhibition, the threshold for pore opening is reached. Lack of an effect may be due to inhibition of CypD binding to a PTP core or regulatory protein (e.g. ANT, P i C, ATP synthase) or associated with the CsA-insensitive pore opening at high [Ca 2+ ]. Studies using the mitochondrial 2-deoxy-[ [40, 41, 109, 168] . These data, as well as other studies demonstrating a wide-range physiological role of CypD, indicate the importance of developing new compounds that can block PTP opening independent of CypD inhibition. Most recently, several groups studied novel compounds that could inhibit pore opening with no effect on CypD. Particularly, N-phenylbenzamides [169] , cinnamic anilides [170] [171] [172] , and isoxazoles [173] have emerged as potent inhibitors of the PTP. CypD-independent effects of these inhibitors have been proven mostly in isolated mitochondria where they were able to inhibit PTP opening in response to Ca 2+ overload and oxidative stress. One of the most promising compounds from cinnamic anilides, (E)-3-(4-fluoro-3-hydroxy-phenyl)-N-naphthalen-1-yl-acrylamide 22 inhibited PTP opening and reduced IR injury in the rabbit model of myocardial infarction [170] .
Thus, new PTP inhibitors lack potential limitations associated with inhibition of physiological function of all cyclophilins including CypD, thereby avoiding off-target effects of CsA and its analogs. However, further studies are required to elucidate the mechanism, toxicity, and therapeutic efficacy of these compounds. Also, lack of knowledge of the PTP molecular identity is the main obstacle in determining a pore component(s) that can be targeted by new PTP inhibitors.
Clinical studies
Myocardial preservation during the first few minutes of reperfusion, which induce additional severe damage to the ischemic myocardium, is the main therapeutic goal in MI patients. PCI and thrombolytic therapy, which are the primary and broadly accepted therapeutic strategies, do not provide adequate cardioprotection and thus, emphasizes the importance of preclinical and clinical studies in this area [174, 175] . There are many challenges in translating positive results of animal studies into clinical therapy, and one of them is the comparability of animal models with the human condition for understanding the pathogenesis and treatment of diseases [176, 177] . For instance, in animal studies elucidating therapeutic strategies to reduce reperfusion damage to the myocardium, infarction size is mostly more than 30% of the left ventricle. Cardioprotective effects of additional therapeutic interventions at reperfusion occur when the infarct size exceeds 20% [176] . Therefore, the beneficial effects of additional treatment observed in animal models cannot be seen in approximately 75% of MI patients receiving reperfusion therapy who have the infarct size equal or less than 20% of the left ventricle [177] . In addition, animal models mostly use 30-40 min of ischemia followed by reperfusion. However, door-to-balloon times for most MI patients in the United States are substantially longer and can reach 90-120 min [178] . These studies suggest that: (1) animal models of MI for the interpretation of the efficiency of reperfusion therapy do not completely simulate human MI, and (2) inclusion of patients with small infarction to clinical trials can significantly dilute results of clinical outcomes in treatment groups. Large animal models (canine or porcine model of MI) are more clinically relevant in pre-clinical studies.
We will briefly discuss results of clinical studies on targeting CypD for prevention of PTP-mediated reperfusion injury. Initial translational studies on human atrial tissue harvested from patients undergoing cardiac surgery revealed protective effects CsA (0.2 µM) against in vitro simulated IR [179] or lethal hypoxia/reoxygenation [180] injury and improved cell survival and recovery of baseline contractile function. Clinical studies that were initiated in 2008 on small groups of patients with MI demonstrated that administration of an intravenous bolus of CsA (2.5 mg/kg, IV) prior to PCI [181] , sternotomy [182] , and aortic clamping [183] significantly reduced MI size and improved post-operative recovery. On the other hand, administration of CsA before thrombolysis with streptokinase did not reduce myocardial injury or arrhythmias in patients with acute STEMI [184] . Based on successful preclinical and clinical studies, in 2014 a large multicenter, double-blind, randomized phase III clinical trial Cyclosporine and Prognosis in Acute Myocardial Infarction Patients (CIRCUS) was conducted in 970 patients with an acute STEM undergoing PCI to determine whether CsA (2.5 mg/kg, IV) improves clinical outcomes of the patients after 1 year [185] . However, these studies found that CsA did not improve immediate outcomes (cumulative creatine kinase release, infarction size) and did not prevent long-term adverse left ventricular remodeling in comparison with placebo [20] .
Several factors such as the severity of infarction, a quite narrow time window for protection, the vehicle for dissolving of CsA, masking of binding site of CypD for CsA by IR-induced post-translational modification(s), route, dose, timing of administration that would be appropriate for CsA to inhibit CypD, among others, should be discussed to find the factors responsible for the lack of cardioprotection in the CIRCUS trial. Nevertheless, these studies challenge the clinical use of CsA and other CypD inhibitors for cardioprotection. These studies also emphasize the importance of future studies to clarify whether CypD is a feasible target for inhibition that can protect the heart and other organ/tissues from IR injury.
Conclusions and perspectives
Intensive studies during the last 20 years led to discovery of several overviews to be considered for the development of new therapeutic strategies for prevention PTP-mediated IR injury. First, PTP opening at low conductance regulates mitochondrial Ca 2+ homeostasis and generates Ca 2+ waves through the Ca 2+ -induced Ca 2+ release mechanism. Second, CypD has PTP-independent functions in the cell and participates in the regulation of energy metabolism and mitochondrial bioenergetics. Third, sustained inhibition of CypD exerts detrimental effects on cell/heart function. Fourth, PTP remains closed during the ischemic period, and opens in the first minutes of reperfusion concurring with pH i recovery. Fifth, the extent of PTP opening in response to oxidative stress is different in spatially divergent subpopulations (SSM and IFM) of heart mitochondria due to variability in CRC and ROS production. Sixth, CsA inhibits not only CypD but all cyclophilins in the cell and hence, may have PTP-independent detrimental effects. Seventh, CsA and its analogs (e.g. SfA, NIM811, Debio-025) exert cardioprotective effects at a narrow range of concentrations (in vitro: 0.2-1.0 µM and in vivo: 1-5 mg/kg), and have detrimental effects at high concentrations. Eighth, genetic ablation or pharmacological inhibition of CypD has a little or no effect on the PTP at high mitochondrial Ca 2+ levels which reach the threshold for pore opening. Ninth, lack of knowledge on the precise molecular identity of the PTP complex and regulation of pore opening are the major obstacles to the development of new pharmacological compounds targeting the PTP. Importantly, heterogeneity of IR-induced injury on cardiac tissue, cardiomyocyte, and mitochondria levels, where the physiological function of CypD and PTP coincides with pathological pore opening, presumably plays a decisive role in the therapeutic action of CsA and its analogs. It requires precise therapeutic intervention for specific targeting that would only prevent pathological consequences of pore opening. Based on a growing number of studies that demonstrate an essential physiological role of CypD in mitochondrial metabolism and function, it is challenging to consider CypD as a viable and promising target for cardioprotection. A myriad of limitations associated with physiological function of CypD and pharmacological effects of CypD inhibitors such as CsA, urges development of new inhibitors that can prevent PTP opening without targeting CypD. Targeting pathological mitochondrial swelling that develops through both PTPdependent and PTP-independent mechanisms can be considered as a viable therapeutic strategy in prevention of mitochondria-mediated IR injury in the heart. 
